Nanoparticle formulations of cisplatin for cancer therapy

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 8, Issue 5, 2016, Pages 776-791

  Duan, Xiaopin ^a   He, Chunbai ^a   Kron, Stephen J ^a   Lin, Wenbin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES; NANOPARTICLES; TISSUE; TUMORS;

ACQUIRED RESISTANCE; CHEMOTHERAPEUTIC AGENTS; CLINICAL SETTINGS; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY AND RETENTION EFFECT; NANOPARTICLE FORMULATION; NORMAL-TISSUE TOXICITY; THERAPEUTIC RATIOS;

PLATINUM COMPOUNDS;

CARBON NANOTUBE; CISPLATIN; COORDINATION POLYMER; GOLD NANOPARTICLE; IRON NANOPARTICLE; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOCAPSULE; NANOPARTICLE; POLYMER; POLYMERIC CONJUGATE; POLYMERIC MICELLE; POLYMERIC NANOPARTICLE; POLYSILSESQUIOXANE NANOPARTICLE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; HUMAN; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; REVIEW;

EID: 84981713461     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1390     Document Type: Review

References (120)

1. Rosenberg B, Vancamp L. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385–386.
2. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010, 39:8113–8127.
3. Ali I, Wani WA, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. Anticancer Agents Med Chem 2013, 13:296–306.
4. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003, 4:889–901.
5. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005, 22:441–445.
6. Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. BBA Rev Cancer 1806, 2010:172–182.
7. Marrache S, Pathak RK, Dhar S. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc Natl Acad Sci USA 2014, 111:10444–10449.
8. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189–207.
9. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles. Proc Natl Acad Sci USA 2008, 105:17356–17361.
10. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 2011, 108:1850–1855.
11. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003, 63:8977–8983.
12. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005, 93:678–687.
13. Lin X, Zhang Q, Rice J, Stewart D, Nowotnik D, Howell S. Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer 2004, 40:291–297.
14. Xiong Y, Jiang W, Shen Y, Li H, Sun C, Ouahab A, Tu J. A poly(γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 2012, 33:7182–7193.
15. Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR, Collins JG. Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J Inorg Biochem 2009, 103:373–380.
16. Krieger ML, Eckstein N, Schneider V, Koch M, Royer H-D, Jaehde U, Bendas G. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010, 389:10–17.
17. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002, 99:130–137.
18. Lee SM, O'Halloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc 2010, 132:17130–17138.
19. Guo S, Miao L, Wang Y, Huang L. Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release 2014, 174:137–142.
20. Guo S, Wang Y, Miao L, Xu Z, Lin CM, Zhang Y, Huang L. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 2013, 7:9896–9904.
21. Thierry B, Al-Ejeh F, Khatri A, Yuan Z, Russell PJ, Ping S, Brown MP, Majewski P. Multifunctional core–shell magnetic cisplatin nanocarriers. Chem Commun 2009:7348–7350.
22. Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc 2009, 131:14652–14653.
23. Tao Z, Toms B, Goodisman J, Asefa T. Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs. ACS Nano 2010, 4:789–794.
24. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. Targeted single-wall carbon nanotube-mediated Pt (IV) prodrug delivery using folate as a homing device. J Am Chem Soc 2008, 130:11467–11476.
25. Rieter WJ, Pott KM, Taylor KML, Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc 2008, 130:11584–11585.
26. Della Rocca J, Huxford RC, Comstock-Duggan E, Lin W. Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release. Angew Chem Int Ed 2011, 123:10514–10518.
27. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surf B Biointerfaces 2010, 75:1–18.
28. Moreno D, Zalba S, Navarro I, Tros de Ilarduya C, Garrido MJ. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice. Eur J Pharm Biopharm 2010, 74:265–274.
29. Moreno D, De Ilarduya CT, Bandrés E, Buñuales M, Azcona M, García-Foncillas J, Garrido MJ. Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm 2008, 68:503–512.
30. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 2007, 67:1–8.
31. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 2009, 71:190–195.
32. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002, 79:123–135.
33. Feldhaeusser B, Platt SR, Marrache S, Kolishetti N, Pathak RK, Montgomery DJ, Reno LR, Howerth E, Dhar S. Evaluation of nanoparticle delivered cisplatin in beagles. Nanoscale 2015, 7:13822–13830.
34. Cheng Q, Shi H, Huang H, Cao Z, Wang J, Liu Y. Oral delivery of a platinum anticancer drug using lipid assisted polymeric nanoparticles. Chem Commun 2015, 51:17536–17539.
35. Miller MA, Zheng Y-R, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun 2015, 6:8692. doi:10.1038/ncomms9692.
36. Xu X, Xie K, Zhang X-Q, Pridgen EM, Park GY, Cui DS, Shi J, Wu J, Kantoff PW, Lippard SJ, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci USA 2013, 110:18638–18643.
37. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 2010, 107:17939–17944.
38. Pathak RK, Dhar S. A nanoparticle cocktail: temporal release of predefined drug combinations. J Am Chem Soc 2015, 137:8324–8327.
39. Zhen X, Wang X, Xie C, Wu W, Jiang X. Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles. Biomaterials 2013, 34:1372–1382.
40. Ding D, Zhu Z, Liu Q, Wang J, Hu Y, Jiang X, Liu B. Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors. Eur J Pharm Biopharm 2011, 79:142–149.
41. Kim J-H, Kim Y-S, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008, 127:41–49.
42. Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, De Totero D, Aiello C, Viale M. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin–alginate complex. J Control Release 2007, 121:110–123.
43. Jeong YI, Kim ST, Jin SG, Ryu HH, Jin YH, Jung TY, Kim IY, Jung S. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 2008, 97:1268–1276.
44. Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML. Intralymphatic chemotherapy using a hyaluronan–cisplatin conjugate. J Surg Res 2008, 147:247–252.
45. Cohen MS, Cai S, Xie Y, Forrest ML. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg 2009, 198:781–786.
46. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids 2013, 2:e110.
47. Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release 2013, 172:699–706.
48. Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci USA 2010, 107:12435–12440.
49. Xu P, Van Kirk EA, Murdoch WJ, Zhan Y, Isaak DD, Radosz M, Shen Y. Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 2006, 7:829–835.
50. Aryal S, Hu C-MJ, Zhang L. Polymer−cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2009, 4:251–258.
51. Huang Y, Tang Z, Zhang X, Yu H, Sun H, Pang X, Chen X. pH-triggered charge-reversal polypeptide nanoparticles for cisplatin delivery: preparation and in vitro evaluation. Biomacromolecules 2013, 14:2023–2032.
52. Nishiyama N, Yokoyama M, Aoyagi T, Okano T, Sakurai Y, Kataoka K. Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum (II) and poly (ethylene glycol)-poly (α, β-aspartic acid) block copolymer in an aqueous medium. Langmuir 1999, 15:377–383.
53. Song W, Li M, Tang Z, Li Q, Yang Y, Liu H, Duan T, Hong H, Chen X. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol Biosci 2012, 12:1514–1523.
54. Duan X, Liu D, Chan C, Lin W. Polymeric micelle-mediated delivery of DNA-targeting organometallic complexes for resistant ovarian cancer treatment. Small 2015, 11:3962–3972.
55. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res 2001, 18:1035–1041.
56. Plummer R, Wilson R, Calvert H, Boddy A, Griffin M, Sludden J, Tilby M, Eatock M, Pearson D, Ottley C. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer 2011, 104:593–598.
57. Xiao H, Song H, Yang Q, Cai H, Qi R, Yan L, Liu S, Zheng Y, Huang Y, Liu T, et al. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012, 33:6507–6519.
58. Song W, Tang Z, Li M, Lv S, Sun H, Deng M, Liu H, Chen X. Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomater 2014, 10:1392–1402.
59. Croy S, Kwon G. Polymeric micelles for drug delivery. Curr Pharm Des 2006, 12:4669–4684.
60. Song H, Wang R, Xiao H, Cai H, Zhang W, Xie Z, Huang Y, Jing X, Liu T. A cross-linked polymeric micellar delivery system for cisplatin(IV) complex. Eur J Pharm Biopharm 2013, 83:63–75.
61. Xiao H, Qi R, Liu S, Hu X, Duan T, Zheng Y, Huang Y, Jing X. Biodegradable polymer−cisplatin (IV) conjugate as a pro-drug of cisplatin (II). Biomaterials 2011, 32:7732–7739.
62. Huynh VT, Binauld S, de Souza PL, Stenzel MH. Acid degradable cross-linked micelles for the delivery of cisplatin: a comparison with nondegradable cross-linker. Chem Mater 2012, 24:3197–3211.
63. Xu P, Van Kirk EA, Li S, Murdoch WJ, Ren J, Hussain MD, Radosz M, Shen Y. Highly stable core-surface-crosslinked nanoparticles as cisplatin carriers for cancer chemotherapy. Colloid Surf B Biointerfaces 2006, 48:50–57.
64. Gianasi E, Wasil M, Evagorou E, Keddle A, Wilson G, Duncan R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999, 35:994–1002.
65. Gianasi E, Buckley RG, Latigo J, Wasil M, Duncan R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J Drug Target 2002, 10:549–556.
66. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, de Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz J-P. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004, 10:3386–3395.
67. Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z. Poly (γ, l-glutamic acid)–cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006, 27:5958–5965.
68. Feng Z, Lai Y, Ye H, Huang J, Xi XG, Wu Z. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives. Cancer Sci 2010, 101:2476–2482.
69. Yellepeddi VK, Kumar A, Palakurthi S. Surface modified poly (amido) amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv 2009, 6:835–850.
70. Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 2011, 31:897–906.
71. Bellis E, Hajba L, Kovacs B, Sandor K, Kollar L, Kokotos G. Three generations of α, γ-diaminobutyric acid modified poly (propyleneimine) dendrimers and their cisplatin-type platinum complexes. J Biochem Biophys Methods 2006, 69:151–161.
72. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ. Evaluation of anionic half generation 3.5–6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 2011, 105:1115–1122.
73. Mallick A, More P, Ghosh S, Chippalkatti R, Chopade BA, Lahiri M, Basu S. Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces 2015, 7:7584–7598.
74. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999, 43:1–7.
75. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z, Turner N. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998, 46:155–165.
76. Seetharmu N, Kim E, Hochster H, Martin F, Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010, 30:541–545.
77. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, Anderson H, Ranson M. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006, 95:822–828.
78. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004, 53:329–336.
79. Terwogt JMM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, Wim W, Schot M, Welbank H, Voest EE. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002, 49:201–210.
80. Boulikas T. Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009, 18:1197–1218.
81. Stathopoulos G, Boulikas T. Lipoplatin formulation review article. J Drug Deliv 2012, 2011. doi:10.1155/2012/581363.
82. Jehn C, Boulikas T, Kourvetaris A, Kofla G, Possinger K, Lüftner D. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008, 28:3961–3964.
83. Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B, Fantini M, Nicoletti S, Drudi F, Panzini I, Tamburini E. Lipoplatin™ monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 2009, 21:86–90.
84. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C. Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010, 68:240–247.
85. de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam M-H. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer 2010, 46:3016–3021.
86. Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, Kudoh T, Chen L, Li Y, Okada M, et al. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm 2010, 391:274–283.
87. Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997, 3:373–379.
88. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005, 23:3495–3501.
89. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 2006, 58:759–764.
90. Júnior ÁD, Mota LG, Nunan EA, Wainstein AJ, Wainstein APD, Leal AS, Cardoso VN, De Oliveira MC. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007, 80:659–664.
91. Carvalho Júnior A, Vieira F, De Melo V, Lopes M, Silveira J, Ramaldes G, Garnier-Suillerot A, Pereira-Maia E, De Oliveira M. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res 2007, 40:1149–1157.
92. Burger KN, Staffhorst RW, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM, de Kruijff B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 2002, 8:81–84.
93. Hamelers IH, De Kroon AI. Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs. J Liposome Res 2007, 17:183–189.
94. Melanie K, Heike Z, Sibylle BS, Hartmut O, Matthias Z, Christian B, Rudolf H, Karl-Jürgen H, Werner AK, Ingrid H. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys Med Biol 2009, 54:5109.
95. Babincová M, Altanerova V, Altaner C, Bergemann C, Babinec P. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia. IEEE Trans Nanobiosci 2008, 7:15–19.
96. Wagstaff AJ, Brown SD, Holden MR, Craig GE, Plumb JA, Brown RE, Schreiter N, Chrzanowski W, Wheate NJ. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg Chim Acta 2012, 393:328–333.
97. 4 nanoparticles for target-specific platin delivery. J Am Chem Soc 2009, 131:4216–4217.
98. 2S nanoparticles for potential cancer therapy: cytotoxicity, in vitro carcinogenicity, and cellular uptake. J Biomed Mater Res A 2008, 85A:787–796.
99. Comenge J, Romero FM, Sotelo C, Domínguez F, Puntes V. Exploring the binding of Pt drugs to gold nanoparticles for controlled passive release of cisplatin. J Control Release 2010, 148:e31–e32.
100. Craig GE, Brown SD, Lamprou DA, Graham D, Wheate NJ. Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval? Inorg Chem 2012, 51:3490–3497.
101. Min Y, Mao C-Q, Chen S, Ma G, Wang J, Liu Y. Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew Chem Int Ed 2012, 51:6742–6747.
102. Min Y, Mao C, Xu D, Wang J, Liu Y. Gold nanorods for platinum based prodrug delivery. Chem Commun 2010, 46:8424–8426.
103. Comenge J, Sotelo C, Romero F, Gallego O, Barnadas A, Parada TG-C, Domínguez F, Puntes VF. Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS One 2012, 7:e47562.
104. Yang P, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev 2012, 41:3679–3698.
105. Gu J, Su S, Li Y, He Q, Zhong J, Shi J. Surface modification−complexation strategy for cisplatin loading in mesoporous nanoparticles. J Phys Chem Lett 2010, 1:3446–3450.
106. Lin C-H, Cheng S-H, Liao W-N, Wei P-R, Sung P-J, Weng C-F, Lee C-H. Mesoporous silica nanoparticles for the improved anticancer efficacy of cisplatin. Int J Pharm 2012, 429:138–147.
107. Gu J, Liu J, Li Y, Zhao W, Shi J. One-pot synthesis of mesoporous silica nanocarriers with tunable particle sizes and pendent carboxylic groups for cisplatin delivery. Langmuir 2012, 29:403–410.
108. Bhirde AA, Patel S, Sousa AA, Patel V, Molinolo AA, Ji Y, Leapman RD, Gutkind JS, Rusling JF. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine 2010, 5:1535–1546.
109. Vashist SK, Zheng D, Pastorin G, Al-Rubeaan K, Luong JH, Sheu F-S. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 2011, 49:4077–4097.
110. Li J, Yap SQ, Yoong SL, Nayak TR, Chandra GW, Ang WH, Panczyk T, Ramaprabhu S, Vashist SK, Sheu FS, et al. Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. Carbon 2012, 50:1625–1634.
111. Guven A, Rusakova IA, Lewis MT, Wilson LJ. Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials 2012, 33:1455–1461.
112. Ajima K, Murakami T, Mizoguchi Y, Tsuchida K, Ichihashi T, Iijima S, Yudasaka M. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano 2008, 2:2057–2064.
113. Della Rocca J, Liu D, Lin W. Nanoscale metal–organic frameworks for biomedical imaging and drug delivery. Acc Chem Res 2011, 44:957–968.
114. Huxford-Phillips RC, Russell SR, Liu DM, Lin WB. Lipid-coated nanoscale coordination polymers for targeted cisplatin delivery. RSC Adv 2013, 3:14438–14443.
115. He C, Lu K, Liu D, Lin W. Nanoscale metal–organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc 2014, 136:5181–5184.
116. Liu D, Poon C, Lu K, He C, Lin W. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun 2014, 5. doi:10.1038/ncomms5182.
117. He C, Liu D, Lin W. Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano 2015, 9:991–1003.
118. He C, Liu D, Lin W. Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. Biomaterials 2015, 36:124–133.
119. Vivero-Escoto JL, Rieter WJ, Lau H, Huxford-Phillips RC, Lin W. Biodegradable polysilsesquioxane nanoparticles as efficient contrast agents for magnetic resonance imaging. Small 2013, 9:3523–3531.
120. Della Rocca J, Werner ME, Kramer SA, Huxford-Phillips RC, Sukumar R, Cummings ND, Vivero-Escoto JL, Wang AZ, Lin W. Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomed Nanotechnol Biol Med 2014, 11:31–38.